Friedman Samuel H, Harley Russell A, Williams Jacob, Forcucci Jessica A, Ramakrishnan Viswanathan, Strange Charlie, Silver Richard M, Feghali-Bostwick Carol, Argula Rahul G
Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.
Department of Pathology & Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA.
J Scleroderma Relat Disord. 2024 Nov 27:23971983241296721. doi: 10.1177/23971983241296721.
Advances in pulmonary arterial hypertension therapies have led to improvements in the quality of life and survival for patients with idiopathic pulmonary arterial hypertension, but these trends have not uniformly translated to patients with systemic sclerosis-associated pulmonary arterial hypertension. In order to better understand the heterogeneity in treatment response and survival, we aimed to examine the histological and immunophenotypic differences between the systemic sclerosis-associated pulmonary arterial hypertension and idiopathic pulmonary arterial hypertension pulmonary vasculopathies. We performed a semi-quantitative lung morphometry-based analysis comparing sections obtained from systemic sclerosis-associated pulmonary arterial hypertension (n = 24), idiopathic pulmonary arterial hypertension (n = 9), and control (n = 13) bio-banked lung tissue specimens. H&E (Hematoxylin and Eosin) and VVG (Verhoeff-Van Gieson)-stained lung sections were analyzed for interstitial and vascular pathology. Immunohistochemistry was used to stain for an array of inflammatory and fibrosis mediators. Baseline demographic and hemodynamic data for each patient were collected via chart review at the time of lung explantation. Plexiform lesions were present in 5/9 (55%) of idiopathic pulmonary arterial hypertension samples, but absent in all systemic sclerosis-associated pulmonary arterial hypertension samples (0/24). Systemic sclerosis-associated pulmonary arterial hypertension lungs demonstrated significantly worse interstitial fibrosis (p = 0.0001) and interstitial cellularity (p = 0.0002) compared to idiopathic pulmonary arterial hypertension lungs. The degree of smooth muscle hypertrophy and pulmonary artery intimal proliferation were not different between systemic sclerosis-associated pulmonary arterial hypertension and idiopathic pulmonary arterial hypertension lungs. Immunohistochemistry analysis revealed that systemic sclerosis-associated pulmonary arterial hypertension lungs exhibited increased interstitial infiltration of CD3 T-cells (p = 0.009), CD20 B-cells (p = 0.01), and CD163 macrophages (p = 0.048) when compared to idiopathic pulmonary arterial hypertension and control lungs. Systemic sclerosis-associated pulmonary arterial hypertension lungs display a distinct pulmonary vascular pathology as well as significant interstitial fibrosis when compared to idiopathic pulmonary arterial hypertension lungs.
肺动脉高压治疗的进展已使特发性肺动脉高压患者的生活质量和生存率得到改善,但这些趋势并未一致地转化到系统性硬化症相关肺动脉高压患者身上。为了更好地理解治疗反应和生存的异质性,我们旨在研究系统性硬化症相关肺动脉高压与特发性肺动脉高压肺血管病变之间的组织学和免疫表型差异。我们进行了一项基于半定量肺形态学的分析,比较了取自系统性硬化症相关肺动脉高压(n = 24)、特发性肺动脉高压(n = 9)和对照(n = 13)的生物样本库肺组织标本的切片。对苏木精和伊红(H&E)染色以及韦尔霍夫-范吉森(VVG)染色的肺切片进行间质和血管病理学分析。免疫组织化学用于对一系列炎症和纤维化介质进行染色。通过在肺移植时查阅病历收集每位患者的基线人口统计学和血流动力学数据。丛状病变在5/9(55%)的特发性肺动脉高压样本中存在,但在所有系统性硬化症相关肺动脉高压样本中均不存在(0/24)。与特发性肺动脉高压肺相比,系统性硬化症相关肺动脉高压肺表现出明显更严重的间质纤维化(p = 0.0001)和间质细胞增多(p = 0.0002)。系统性硬化症相关肺动脉高压肺与特发性肺动脉高压肺之间的平滑肌肥大程度和肺动脉内膜增殖程度没有差异。免疫组织化学分析显示,与特发性肺动脉高压肺和对照肺相比,系统性硬化症相关肺动脉高压肺表现出CD3 T细胞(p = 0.009)、CD20 B细胞(p = 0.01)和CD163巨噬细胞(p = 0.048)的间质浸润增加。与特发性肺动脉高压肺相比,系统性硬化症相关肺动脉高压肺表现出独特的肺血管病理学以及明显的间质纤维化。